Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade

Immunotherapy with monoclonal antibodies targeting immune checkpoint molecules, including programmed death-1 (PD-1), PD ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen (CTLA)-4, has become prominent in the treatment of many types of cancer. However, a significant number of patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Weilei, Wang, Guosheng, Wang, Yian, Riese, Matthew J., You, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554032/
https://www.ncbi.nlm.nih.gov/pubmed/33083746
http://dx.doi.org/10.1016/j.isci.2020.101580

Ejemplares similares

Ejemplares similares